Gunjan Shah
@GunjanLShah
Followers
1K
Following
9K
Media
165
Statuses
452
Joined October 2009
RT @RahulBanerjeeMD: This is re(n)ally awesome!!!. Well-written guidelines re: kidney transplant in myeloma et al by tour de force team: @v….
0
12
0
RT @RShouval: 🚨 Just out @NatureMedicine!.Introducing InflaMix—a point-of-care tool that identifies an #inflammatory 🔥 signature predictive….
nature.com
Nature Medicine - A preinfusion circulatory inflammation biomarker-based signature predicts the likelihood of treatment failure in patients with non-Hodgkin lymphoma who were treated with CAR-T...
0
42
0
RT @MSK_DeptOfMed: New research from @MSKCancerCenter takes a step toward off-the-shelf CAR T cell therapy for #cancer. Author Karlo Perica….
mskcc.org
Learn how researchers are making better CAR T cells by taking a lesson from viruses.
0
15
0
RT @brandon_imber: Effective cytoreduction in the bridging period can significantly improve outcomes for those planned for CAR T cells - ra….
pubmed.ncbi.nlm.nih.gov
This is the first study to use radiomics to quantify disease burden pre- and post-BT in a large real-world large B-cell lymphoma cohort. We demonstrate that effective BT can enable initially high-d...
0
7
0
RT @MalinHultcrantz: Colesevelam is highly effective and safe for treatment of lenalidomide associated diarrhea: .- Phase 2 trial, 25 pts.-….
0
14
0
RT @MScordoMD: TCT Community, mark your calendars for one of the most unique conferences of the year. Insightful, practical, & forward-thin….
0
7
0
RT @ASTCT_Journal: A total cost of care was compared for letermovir prophylaxis versus preemptive therapy. For high-risk pts, letermovir de….
0
17
0
RT @FDAOncology: FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for multiple myeloma. htt….
fda.gov
On July 30, 2024, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Research & Development, LLC) in combination with bortezomib, lenalidomide, and...
0
25
0
RT @RossFirestone: Our work with @szusmani and @DavidJChungMD at @MSKCancerCenter looking at antigen escape with BCMA-targeting therapies i….
0
11
0
RT @sghmd: Remember when we used to avoid mismatched unrelated donor transplants for fear of worse GVHD and NRM outcomes? Those days are ov….
0
13
0
RT @UrviShahMD: Today marks the 140th anniversary of @MSKCancerCenter founding in 1884 as the New York Cancer Hospital! It was renamed, Mem….
0
8
0
RT @VincentRK: Just out: International Myeloma Working Group guidelines CAR-T cell treatment in myeloma. For Limited time: Link to Free….
thelancet.com
Chimeric antigen receptor (CAR) T-cell therapy has shown promise in patients with late-line refractory multiple myeloma, with response rates ranging from 73 to 98%. To date, three products have been...
0
47
0
